Dr. Lindsey's Multiple Sclerosis Website

ECTRIMS 2011

Home
ACTRIMS Forum 2017
ECTRIMS 2016
Tecfidera update September, 2016
ECTRIMS 2015
AAN 2015
ACTRIMS-ECTRIMS 2014
AAN 2014
Current Treatments (updated 7/7/13)
Gilenya (updated 4/20/2012)
Tysabri and PML
Ampyra
Recent and current research
Old meetings
New diagnosis of MS
Multiple Sclerosis Basic Information
Interferon versus Glatiramer--update 11/07
Talk on stem cells--2/13/08
About Dr. Lindsey
Research Interests
Map/Directions
Links
Clinic information
Contact Us
I attended the ECTRIMS meeting October 19-22, 2011 in Amsterdam.  This year there were a number of important clinical trials, many of which were Phase III results from drugs which looked very promising in Phase II.

BG12:  The most important results were from a Phase III study of a drug called BG12.  This is an oral medication, given either 2 or 3 times a day. They did a 96 week study with over 1200 subjects in 3 groups.  The annual relapse rate on placebo was 0.364, while it was 0.172 on lower dose BG12 and 0.189 on the higher dose of BG12.  This is a reduction of 53 or 48% in the relapse rate.  There was also a marked effect on MRI activity, with a reduction of about 90% in enhancing lesions and 85% in new T2 lesions.  The main side effects were flushing and GI irritation.  These are impressive results, both for efficacy and safety.  In their Phase II study (see the report from ECTRIMS 2009) this drug reduced relapse rate by 30%, so these results are a little surprising.  A second phase III study is in progress, and results should be available soon.  If they see the same benefits, this will be an attractive medicine. 

Laquinimod:  results of the second phase III trial comparing laquinimod, placebo and Avonex.  Laquinimod had a modest effect on number of relapses, decreasing them by about 18%.  Safety appears good.  This agent has the advantage of being oral, but doesn’t offer any increased effectiveness over available treatments.  (see AAN 2011 for other results with this drug.)

Daclizumab:  This is a monoclonal antibody given as a once a month injection.  It binds the interleukin-2 receptor.  It decreased relapse rate by about 50% compared to placebo, and also decreased disability and MRI activity.  There was one death from an infection, and a small increase in the rate of serious infections. 

Alemtuzumab:  This is a monoclonal antibody that depletes a wide range of white blood cells.  It is given yearly in a series of infusions over 5 days.  In this study, they treated recently diagnosed subjects who had not received any previous treatment, and compared the alemtuzumab to Rebif.  Alemtuzumab decreased relapse rate by 55% compared to Rebif (note this is not compared to placebo like the other trials).  It also decreased disability slightly.  Notable side effects included autoimmune thyroid and platelet problems as seen in previous studies.  This looks like a very effective medicine, but with some concerning side effects.  These results are very similar to their phase II trial reported in 2008, and a second phase III study is in progress. 

Atacicept:  One puzzling result was a study of atacicept, a protein that interferes with B cell activity.  Depletion of B cells is very effective for MS, so we expected that atacicept would also improve MS.  But instead, it seemed to increase disease activity.  The difference in effect between blocking B cell activity and getting rid of B cells completely is unexplained and unexpected.  But it reinforces the point that often treatments do not do what we expect they will, and every drug needs rigorous testing before we accept it as effective.    

J. William Lindsey, MD
University of Texas Multiple Sclerosis Research Group
Houston, Texas

copyright 2007-2017 John William Lindsey